236 related articles for article (PubMed ID: 15650000)
1. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model.
Alou L; Aguilar L; Sevillano D; Giménez MJ; Echeverría O; Gómez-Lus ML; Prieto J
J Antimicrob Chemother; 2005 Feb; 55(2):209-13. PubMed ID: 15650000
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia].
Cousson J; Floch T; Vernet-Garnier V; Appriou M; Petit JS; Jovenin N; Lamiable D; Hoizey G
Pathol Biol (Paris); 2005; 53(8-9):546-50. PubMed ID: 16023303
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
[TBL] [Abstract][Full Text] [Related]
5. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
[TBL] [Abstract][Full Text] [Related]
6. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
[TBL] [Abstract][Full Text] [Related]
7. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
8. In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia.
Croisier D; Martha B; Piroth L; Chavanet P
Int J Antimicrob Agents; 2008 Dec; 32(6):494-8. PubMed ID: 18804348
[TBL] [Abstract][Full Text] [Related]
9. Chronokinetics of ceftazidime after intramuscular administration to dogs.
Monfrinotti A; Ambros L; Montoya L; Prados AP; Rebuelto M
Chronobiol Int; 2010 May; 27(3):549-59. PubMed ID: 20524800
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.
Boak LM; Li J; Rayner CR; Nation RL
Antimicrob Agents Chemother; 2007 Apr; 51(4):1287-92. PubMed ID: 17242144
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model.
Zhanel GG; Derkatch S; Laing N; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2007 Jan; 59(1):144-7. PubMed ID: 17079238
[TBL] [Abstract][Full Text] [Related]
12. Are beta-lactam breakpoints adequate to define non-susceptibility for all Haemophilus influenzae resistance phenotypes from a pharmacodynamic point of view?
Alou L; Giménez MJ; Sevillano D; Aguilar L; González N; Echeverría O; Torrico M; Coronel P; Prieto J
J Antimicrob Chemother; 2007 Apr; 59(4):652-7. PubMed ID: 17341471
[TBL] [Abstract][Full Text] [Related]
13. Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic model simulating urine concentrations obtained after 2000/125 mg sustained-release co-amoxiclav and 400 mg norfloxacin administration.
Alou L; Aguilar L; Sevillano D; Giménez MJ; Cafini F; Valero E; Relaño MT; Prieto J
J Antimicrob Chemother; 2006 Apr; 57(4):714-9. PubMed ID: 16492718
[TBL] [Abstract][Full Text] [Related]
14. Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation.
Sevillano D; Calvo A; Giménez MJ; Alou L; Aguilar L; Valero E; Carcas A; Prieto J
J Antimicrob Chemother; 2004 Dec; 54(6):1148-51. PubMed ID: 15489246
[TBL] [Abstract][Full Text] [Related]
15. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
Lorente L; Jiménez A; Palmero S; Jiménez JJ; Iribarren JL; Santana M; Martín MM; Mora ML
Clin Ther; 2007 Nov; 29(11):2433-9. PubMed ID: 18158083
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
Burgess DS; Summers KK; Hardin TC
Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacodynamic optimization of ceftazidime against Pseudomonas aeruginosa: continuous infusion or intermittent administration?].
Aguilar L; Giménez MJ; Martín JE; Prieto J
Rev Esp Quimioter; 2005 Mar; 18(1):21-5. PubMed ID: 15915228
[No Abstract] [Full Text] [Related]
19. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.
Mouton JW; den Hollander JG
Antimicrob Agents Chemother; 1994 May; 38(5):931-6. PubMed ID: 8067772
[TBL] [Abstract][Full Text] [Related]
20. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
Benko AS; Cappelletty DM; Kruse JA; Rybak MJ
Antimicrob Agents Chemother; 1996 Mar; 40(3):691-5. PubMed ID: 8851594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
